T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

Blood

Volumn 113, Issue 15, 2009, Pages 3546-3552

  Houot, Roch ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FOLATE RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CLTA4; MONOCLONAL ANTIBODY FR4; MONOCLONAL ANTIBODY GITR; MONOCLONAL ANTIBODY OX40; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL ACTIVATION; CELL POPULATION; DRUG EFFICACY; EFFECTOR CELL; FEMALE; IMMUNOMODULATION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY; VACCINATION;

EID: 65349153756     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-170274     Document Type: Article

References (24)

1. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23:6421-6428.
2. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179:2493-2500.
3. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5: 471-484.
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263-274.
5. Baxter AG, Hodgkin PD. Activation rules: the two - signal theories of immune activation. Nat Rev Immunol. 2002;2:439-446.
6. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004;4:420-431.
7. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336-347.
8. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467-477.
9. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007;27:145-159.
10. Shimizu J, Yamazaki S, Takahashi T, Ishida Y Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135-142.
11. Shevach EM, Stephens GL. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol. 2006;6: 613-618.
12. + regulatory Tcells. J Exp Med. 2005;202:885-891.
13. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. Triggering of OX40 (CD134) on CD4(+)CD25(+) T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood. 2005;105:2845-2851.
14. + Tregs. Blood. 2007;110:2501-2510.
15. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med. 2008;205:825-839.
16. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor im - munogenicity and anatomic site of tumor growth. Cancer Res. 2000;60:5514-5521.
17. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734-1736.
18. Weinberg AD, Rivera MM, Prell R, et al. Engagement of the OX-40 receptor in vivo enhances anti - tumor immunity. J Immunol. 2000;164:2160-2169.
19. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatorymonoclonal antibodies for cancer therapy. Nat RevCancer. 2007; 7:95-106.
20. Beck KE, Blansfield JA, Tran KQ, et al. Enteroco - litis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283-2289.
21. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-8377.
22. Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol. 2003;171: 6251-6259.
23. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23: 6043-6053.
24. Brody J,Ai W, Czerwinski D,et al. Clinical and immunologic responses to a novel in situ lym - phoma vaccine maneuver: preliminary results of a phase II trial of intra-tumoral CpG 7909. J Clin Oncol. Vol 26, No 15S (May 20 Supplement), 2008:3003.